Literature DB >> 31569984

Comment on a Word to the Wise About Intranasal Esketamine.

Wayne C Drevets1, Jaskaran B Singh1, David Hough1, Ella J Daly1, Vanina Popova1, Husseini Manji1.   

Abstract

Keywords:  Esketamine; Ketamine; Major Depressive Disorder; Neurology; Neurophysiology; Opioids; S-Ketamine; Treatment-Resistant Depression

Year:  2019        PMID： 31569984     DOI： 10.1176/appi.ajp.2019.19070688

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  3 in total

1.  Intravenous arketamine for treatment-resistant depression: open-label pilot study.

Authors:  Gustavo C Leal; Igor D Bandeira; Fernanda S Correia-Melo; Manuela Telles; Rodrigo P Mello; Flavia Vieira; Cassio S Lima; Ana Paula Jesus-Nunes; Lívia N F Guerreiro-Costa; Roberta F Marback; Ana Teresa Caliman-Fontes; Breno L S Marques; Marília L O Bezerra; Alberto L Dias-Neto; Samantha S Silva; Aline S Sampaio; Gerard Sanacora; Gustavo Turecki; Colleen Loo; Acioly L T Lacerda; Lucas C Quarantini
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-02-20       Impact factor: 5.270

Review 2.  "Novel Psychopharmacology for Depressive Disorders".

Authors:  Michele Fornaro; Domenico De Berardis; Annalisa Anastasia; Andrea Fusco
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Ketamine-50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms.

Authors:  Samuel Kohtala
Journal:  Pharmacol Rep       Date:  2021-02-20       Impact factor: 3.024
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.